Khalsa A, Olsson B, Henriksson B A
Acta Med Scand. 1979;205(1-2):39-47. doi: 10.1111/j.0954-6820.1979.tb06001.x.
In patients with chronic atrial fibrillation (AF), symptoms and cardiac function may be improved by regularizing the ventricular rhythm, even though the AF persists. This study concerned effects of i.v. and oral verapamil (V) on ventricular regularity. A regularizing effect was observed in 5 out of 10 patients after 0.15 mg of V/kg b.wt.i.v., but in only one patient after 80 mg of V By mouth. V in a dose of 240 mg by mouth resulted in ventricular regularity in 6 out of 10 other patients, 320 mg in a further 2 and 400 mg in the remaining 2 patients. Six patients were given chronic oral therapy in progressively increasing doses. Although ventricular regularity and symptom relief were obtained, intolerable side-effects precluded the evaluation of subjective long-term effects of this therapy in all but one patient. Further investigations, particularly concerning the pharmacokinetic mechanisms of V, are needed before the treatment can be recommended for patients with chronic AF.
在慢性心房颤动(AF)患者中,即使房颤持续存在,通过使心室节律规则化,症状和心脏功能可能会得到改善。本研究关注静脉注射和口服维拉帕米(V)对心室节律规则性的影响。静脉注射0.15mg/kg体重的V后,10名患者中有5名出现节律规则化效应,但口服80mg V后只有1名患者出现该效应。口服240mg V使另外10名患者中的6名心室节律规则化,320mg使另外2名患者出现该效应,400mg使其余2名患者出现该效应。6名患者接受逐渐增加剂量的长期口服治疗。尽管获得了心室节律规则化和症状缓解,但除1名患者外,难以耐受的副作用妨碍了对该治疗主观长期效果的评估。在向慢性房颤患者推荐该治疗之前,需要进一步研究,特别是关于V的药代动力学机制。